Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Differential protective effects of a history of thyroid cancer on breast cancer-specific mortality in patients at age<50years and age≥50years at the diagnosis of breast cancer. by Weiwei Cheng (582223)

Subjects:

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Ofd1 protection of photoreceptors from oxidative stress via decreasing ROS production. by Juan Wang (115708)

“…MNU+Ofd1 CDS: after 661W transfected with pEGFP-Ofd1-CDS for 48h, MNU 500 ug/ml treated for 10 mins. Scale bar: 50μm. (B) Cell viability and proliferation detection in 661W cell using the MTT assay. …”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Cell adhesion to fibronectin is decreased with 50 µM 4N1K treatment. by Pascal Leclair (566971)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

“…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”

Revisiting the sealed heating method–heating cells in a low volume decreases nuclear Chk1. by Andrew J. Massey (239469)

Surface tension versus time of the MHS solution (50 mM) and LNC dispersion containing 50 mM MHS as determined by drop tensiometry. by Celia R. A. Mouzouvi (4347937)